3 Humongous Health-Care Stocks This Week

Published November 10, 2012

3 Humongous Health-Care Stocks This Week

Filed under: drug treatment news articles

The company reported phase 3 results for GALNS, its drug for treating Morquio A syndrome. As you might suspect, those results were very good. Morquio A is very rare, affecting 1,000 to 1,500 patients in the U.S. and no more than 3,000 patients worldwide.
Read more on Motley Fool

Buy Gilead Sciences: HIV And Hepatitis Drugs To Drive Growth

Filed under: drug treatment news articles

Sales for the drug stood at $ 804 million. Truvada has been used for the treatment of HIV since 2004, and was recently granted approval for as an AIDS prevention drug. Previously in our article, we highlighted the potential of a sales increase for this …
Read more on Seeking Alpha